On March 26, 2018, InnoPharmax have signed the licensing agreement with Shandong New Times Pharmaceuticals for Sapropterin Dihydrochloride (BH4) tablets in China and Spain.

On Augest 29, 2022, under the main contract, InnoPharmax and Shandong New Times Pharmaceuticals have signed supplementary agreement to further expend the colaberation regions adding Germany, the United Kingdom and France. The action will facilitate mutual business in European market.

Shandong New Times Pharmaceuticals is one of the members of the Lunan Pharmaceutical Group, a comprehensive pharmaceutical group with integrated production, research and sales of concentrated pharmaceuticals, chemicals and biological products, and is ranked among the top 500 competitive large enterprise groups in China.